Mineralys Therapeutics, Inc. (MLYS)
NASDAQ: MLYS · Real-Time Price · USD
22.88
-0.77 (-3.26%)
At close: Mar 24, 2026, 4:00 PM EDT
23.01
+0.13 (0.57%)
Pre-market: Mar 25, 2026, 5:12 AM EDT

Mineralys Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
38.623.8214.35.232.42
Research & Development
132.01168.5870.3626.2516.31
Total Operating Expenses
170.6192.484.6631.4818.73
Operating Income
-170.6-192.4-84.66-31.48-18.73
Interest Income
15.9514.5912.761.68-0.03
Other Non-Operating Income (Expense)
-0.0100-0.66
Total Non-Operating Income (Expense)
15.9514.5912.761.68-0.68
Pretax Income
-154.65-177.81-71.9-29.8-19.41
Net Income
-154.65-177.81-71.9-29.8-19.41
Net Income to Common
-154.65-177.81-71.9-29.8-19.41
Shares Outstanding (Basic)
68493655
Shares Outstanding (Diluted)
68493655
Shares Change (YoY)
39.38%34.13%600.33%3.67%-7.90%
EPS (Basic)
-2.29-3.66-1.99-5.77-3.89
EPS (Diluted)
-2.29-3.66-1.99-5.77-3.89
Free Cash Flow
-142.43-166.41-81.17-29.22-14.56
Free Cash Flow Per Share
-2.11-3.43-2.24-5.65-2.92
EBITDA
-170.55-192.36-84.66-31.48-18.73
EBIT
-170.6-192.4-84.66-31.48-18.73
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q